• Earlier this year, Novo Nordisk announced a partnership with Hims & Hers Health to offer branded GLP-1 weight-loss drugs through the Hims & Hers telehealth platform, with subscriptions priced at US$39 for the first month and US$149 thereafter, excluding medication costs.
• The tie-up positions Hims & Hers as a key telehealth partner for Novo Nordisk at a time when some employers are limiting GLP-1 coverage, potentially directing more cash-pay patients toward its platform.
• Next, we’ll examine how this Novo Nordisk partnership and expanding GLP-1 access could reshape Hims & Hers’ long-term cash-pay investment narrative.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Hims & Hers Health Investment Narrative Recap

To own Hims & Hers, you need to believe in a broad shift toward cash-pay, direct-to-consumer telehealth where the company becomes a trusted front door for ongoing care. The Novo Nordisk deal taps into that thesis by bringing branded GLP-1s onto the platform, but it also heightens near term concentration risk in weight loss and reinforces the key catalyst and risk: how well Hims & Hers can grow profitably while relying on a few fast-moving categories.

The recent expansion of the Hims & Hers Benefits program, including partners like Dexcom, MyFitnessPal, and Flo Health, ties directly into the GLP-1 story. It shows the company leaning into a broader “weight and metabolic health” ecosystem around these drugs, which may support subscriber engagement but also deepens exposure to any shift in GLP-1 access, regulation, or consumer sentiment.

Yet while GLP 1 access looks exciting on the surface, investors should also be aware of...

Hims & Hers Health's narrative projects $3.8 billion revenue and $164.3 million earnings by 2029. This requires 16.6% yearly revenue growth and a $177.5 million earnings increase from -$13.2 million today.

Uncover how Hims & Hers Health's forecasts yield a $26.82 fair value, a 21% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already expected Hims & Hers to reach about US$4.0 billion in revenue and roughly US$346 million in earnings, but the Novo Nordisk GLP 1 partnership could either reinforce that bullish view on data driven, vertically integrated care or highlight how much the story still hinges on lifestyle medications and regulatory tolerance.

Explore 34 other fair value estimates on Hims & Hers Health - why the stock might be worth over 5x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Hims & Hers Health research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Hims & Hers Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hims & Hers Health's overall financial health at a glance.

Searching For A Fresh Perspective?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 51 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 44 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.